Clinical trial
Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With…
NCT00003897 · University of Wisconsin, Madison, Other · Completed
Key facts
| NCT number | NCT00003897 |
|---|---|
| Title | Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma |
| Official title | Phase I Trial of Immunization Using Particle-Mediated Transfer of Genes for GP-100 and GM-CSF Into Uninvolved Skin of Patients With Melanoma (Summary Last Modified 7/1999) |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | gp100 antigen, sargramostim |
| Enrollment | 18 |
| Start date | May 1, 1999 |
| Primary completion | Mar 1, 2001 |
| Completion | Dec 1, 2006 |
| First posted | Aug 18, 2004 |
| Last update posted | Nov 19, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: